Invention Grant
- Patent Title: Protease inhibitors as antivirals
-
Application No.: US17830185Application Date: 2022-06-01
-
Publication No.: US11753373B2Publication Date: 2023-09-12
- Inventor: Long Mao , Xiao Xu , Namir Shaabani , Can Jin
- Applicant: ACEA Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: ACEA Therapeutics, Inc.
- Current Assignee: ACEA Therapeutics, Inc.
- Current Assignee Address: US CA San Diego
- Agency: McNeill Baur PLLC
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D403/12 ; C07D207/26 ; C07D207/416 ; C07D401/14 ; C07D403/14 ; C07D413/14
Abstract:
Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)
and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
Public/Granted literature
- US20230026438A1 PROTEASE INHIBITORS AS ANTIVIRALS Public/Granted day:2023-01-26
Information query
